CL2012003283A1 - Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. - Google Patents

Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8.

Info

Publication number
CL2012003283A1
CL2012003283A1 CL2012003283A CL2012003283A CL2012003283A1 CL 2012003283 A1 CL2012003283 A1 CL 2012003283A1 CL 2012003283 A CL2012003283 A CL 2012003283A CL 2012003283 A CL2012003283 A CL 2012003283A CL 2012003283 A1 CL2012003283 A1 CL 2012003283A1
Authority
CL
Chile
Prior art keywords
antibody
gdf
antigen
activity
fragment
Prior art date
Application number
CL2012003283A
Other languages
English (en)
Inventor
Trevor Stitt
Esther Latres
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44477626&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2012003283A1 publication Critical patent/CL2012003283A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Anticuerpo humano aislado o un fragmento de unión al antígeno del mismo porque se une o bloquea la actividad biológica de GDF-8 humano maduro de tipo natural; composición farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de GDF-8.
CL2012003283A 2010-05-26 2012-11-23 Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8. CL2012003283A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34855910P 2010-05-26 2010-05-26
US37288210P 2010-08-12 2010-08-12

Publications (1)

Publication Number Publication Date
CL2012003283A1 true CL2012003283A1 (es) 2013-01-25

Family

ID=44477626

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003283A CL2012003283A1 (es) 2010-05-26 2012-11-23 Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8.

Country Status (40)

Country Link
US (5) US8840894B2 (es)
EP (1) EP2576618B1 (es)
JP (1) JP5896993B2 (es)
KR (1) KR101859911B1 (es)
CN (1) CN102933602B (es)
AR (1) AR081221A1 (es)
AU (1) AU2011258342B2 (es)
BR (1) BR112012029986B1 (es)
CA (1) CA2800581C (es)
CL (1) CL2012003283A1 (es)
CO (1) CO6620013A2 (es)
CR (1) CR20120577A (es)
CY (1) CY1119445T1 (es)
DK (1) DK2576618T3 (es)
DO (1) DOP2012000295A (es)
EC (1) ECSP12012309A (es)
ES (1) ES2647389T3 (es)
GT (1) GT201200318A (es)
HR (1) HRP20171499T1 (es)
HU (1) HUE037140T2 (es)
IL (1) IL223003A (es)
JO (1) JO3340B1 (es)
LT (1) LT2576618T (es)
MX (2) MX2012013369A (es)
MY (1) MY157109A (es)
NI (1) NI201200171A (es)
NO (1) NO2576618T3 (es)
NZ (1) NZ603529A (es)
PE (1) PE20130226A1 (es)
PL (1) PL2576618T3 (es)
PT (1) PT2576618T (es)
RS (1) RS56368B1 (es)
RU (2) RU2710156C2 (es)
SG (2) SG10201504092TA (es)
SI (1) SI2576618T1 (es)
TN (1) TN2012000555A1 (es)
TW (2) TWI602917B (es)
UY (1) UY33407A (es)
WO (1) WO2011150008A1 (es)
ZA (1) ZA201208525B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AU2011292197B2 (en) 2010-08-16 2015-05-28 Amgen Inc. Antibodies that bind myostatin, compositions and methods
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2663946T3 (es) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
MY172863A (en) 2012-09-13 2019-12-13 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
CN112933223A (zh) 2012-10-24 2021-06-11 细胞基因公司 用于治疗贫血的方法
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
MX359794B (es) 2013-03-15 2018-10-10 Intrinsic Lifesciences Llc Anticuerpos anti-hepcidina y usos de los mismos.
US11267868B2 (en) 2013-04-02 2022-03-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3564671B1 (en) 2013-08-23 2021-09-29 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
MX2017006521A (es) 2014-11-24 2017-08-09 Somalogic Inc Compuestos de acido nucleico para unirse al factor de diferenciacion de crecimiento 11.
PE20221834A1 (es) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
EP3283519A1 (en) * 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
LT3350220T (lt) 2015-09-15 2021-09-27 Scholar Rock, Inc. Anti pro/latentinio miostatino antikūnai ir jų panaudojimas
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN109071645A (zh) 2016-01-08 2018-12-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
KR102271635B1 (ko) 2016-06-13 2021-07-06 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
CN106770517A (zh) * 2016-12-16 2017-05-31 青岛科技大学 一种检测力竭运动后小鼠骨骼肌肌肉生长抑制素含量的方法
WO2018118713A1 (en) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
FI3565592T3 (fi) 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
CN111479588A (zh) * 2017-12-29 2020-07-31 豪夫迈·罗氏有限公司 用于改善抗vegf抗体的vegf受体阻断选择性的方法
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
BR112020013426A2 (pt) 2018-02-28 2020-12-01 Regeneron Pharmaceuticals, Inc. métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
CN111787981A (zh) 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法
CN111868085A (zh) 2018-03-19 2020-10-30 瑞泽恩制药公司 微芯片毛细管电泳测定法及试剂
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
CN112218877A (zh) 2018-08-27 2021-01-12 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN112601963A (zh) 2018-08-30 2021-04-02 瑞泽恩制药公司 用于表征蛋白质复合物的方法
CN113195532A (zh) * 2018-12-18 2021-07-30 瑞泽恩制药公司 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
CA3116732A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
MX2022003438A (es) 2019-09-24 2022-04-19 Regeneron Pharma Sistemas y metodos para uso y regeneracion de cromatografia.
KR20220104797A (ko) 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
WO2021142269A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
WO2021142331A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
KR102544013B1 (ko) 2020-01-21 2023-06-19 리제너론 파마슈티칼스 인코포레이티드 당질화된 단백질의 전기영동을 위한 탈당질화 방법
EP4204578A1 (en) 2020-08-31 2023-07-05 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
KR20230113280A (ko) 2020-11-25 2023-07-28 리제너론 파마슈티칼스 인코포레이티드 비수성 멤브레인 유화법을 사용한 지속 방출 제형
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
WO2023039457A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
AU2022359898A1 (en) 2021-10-07 2024-03-21 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
WO2023177836A1 (en) 2022-03-18 2023-09-21 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
DE69432815T2 (de) 1993-03-19 2003-12-11 Univ Johns Hopkins Med Wachstumsfaktor-8
JP4544742B2 (ja) 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
MXPA01013232A (es) 1999-07-20 2005-05-24 Pharmexa As Metodo para identificar la actividad de gdf-8.
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
KR20130036378A (ko) * 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
WO2004108157A2 (en) 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
BRPI0418317A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
ES2384176T3 (es) * 2004-03-23 2012-07-02 Eli Lilly & Company Anticuerpos anti-miostatina
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
BRPI0514253A (pt) 2004-08-12 2008-06-03 Wyeth Corp terapia de combinação para diabetes, obesidade e doenças cardiovasculares usando composições contendo inibidores de gdf-8
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1877075A4 (en) * 2005-04-25 2008-07-30 Pfizer ANTIBODIES DIRECTED AGAINST MYOSTATIN
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
KR101135220B1 (ko) * 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP1968621A2 (en) 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
US7699146B1 (en) 2006-04-02 2010-04-20 Fox Factory, Inc. Suspension damper having inertia valve and user adjustable pressure-relief
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
WO2008016314A1 (en) * 2006-08-03 2008-02-07 Orico Limited Myostatin antagonists
PL2066695T3 (pl) 2006-09-05 2013-08-30 Lilly Co Eli Przeciwciała przeciwko miostatynie
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CN100586476C (zh) * 2006-10-13 2010-02-03 中国人民解放军第四军医大学 一种Myostatin特异性抗体的治疗性疫苗及其制备方法
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
PE20090982A1 (es) 2007-11-05 2009-08-13 Novartis Ag Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
AU2010265933B2 (en) 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
ES2663946T3 (es) 2011-11-14 2018-04-17 Regeneron Pharmaceuticals, Inc. Composiciones y métodos para aumentar la masa y la fuerza muscular antagonizando específicamente GDF8 y/o Activina A
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途

Also Published As

Publication number Publication date
ECSP12012309A (es) 2012-12-28
EP2576618A1 (en) 2013-04-10
NI201200171A (es) 2013-04-15
RU2015143242A3 (es) 2019-05-21
US20160340421A1 (en) 2016-11-24
PE20130226A1 (es) 2013-03-15
AU2011258342A1 (en) 2012-12-20
NO2576618T3 (es) 2018-01-13
NZ603529A (en) 2015-07-31
BR112012029986B1 (pt) 2022-05-24
US20190023777A1 (en) 2019-01-24
RU2710156C2 (ru) 2019-12-24
CR20120577A (es) 2013-03-04
SG185455A1 (en) 2012-12-28
CN102933602B (zh) 2016-08-03
US9890212B2 (en) 2018-02-13
ZA201208525B (en) 2013-07-31
RS56368B1 (sr) 2017-12-29
RU2012156938A (ru) 2014-07-10
RU2015143242A (ru) 2018-12-28
AU2011258342B2 (en) 2016-04-21
TN2012000555A1 (en) 2014-04-01
US9260515B2 (en) 2016-02-16
UY33407A (es) 2011-12-01
US8840894B2 (en) 2014-09-23
WO2011150008A1 (en) 2011-12-01
RU2567805C2 (ru) 2015-11-10
MY157109A (en) 2016-05-13
AR081221A1 (es) 2012-07-04
JO3340B1 (ar) 2019-03-13
US20110293630A1 (en) 2011-12-01
TWI602917B (zh) 2017-10-21
LT2576618T (lt) 2017-10-25
PT2576618T (pt) 2017-10-23
MX357145B (es) 2018-06-28
TW201701903A (zh) 2017-01-16
IL223003A0 (en) 2013-02-03
DK2576618T3 (en) 2017-10-02
EP2576618B1 (en) 2017-08-16
MX2012013369A (es) 2013-02-11
BR112012029986A2 (es) 2017-08-22
TW201201838A (en) 2012-01-16
JP5896993B2 (ja) 2016-03-30
JP2013528608A (ja) 2013-07-11
DOP2012000295A (es) 2013-04-15
PL2576618T3 (pl) 2018-01-31
US20140356369A1 (en) 2014-12-04
CO6620013A2 (es) 2013-02-15
CY1119445T1 (el) 2018-03-07
KR20130109981A (ko) 2013-10-08
HUE037140T2 (hu) 2018-08-28
GT201200318A (es) 2014-01-27
HRP20171499T1 (hr) 2017-11-17
CN102933602A (zh) 2013-02-13
US20240067712A1 (en) 2024-02-29
SI2576618T1 (sl) 2017-10-30
CA2800581C (en) 2019-04-09
SG10201504092TA (en) 2015-06-29
CA2800581A1 (en) 2011-12-01
IL223003A (en) 2017-12-31
KR101859911B1 (ko) 2018-05-21
ES2647389T3 (es) 2017-12-21

Similar Documents

Publication Publication Date Title
CL2012003283A1 (es) Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8.
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
AR076195A1 (es) Anticuerpos biespecificos anti-erbb-1/anti-c-met
EA201290919A1 (ru) Индазольные соединения и их применение
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
CL2014002750A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
EA201891433A2 (ru) Состав антитела и терапевтические режимы
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
CO6220870A2 (es) Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
AR074563A1 (es) Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t
GT201400111A (es) Triazolopiridinas sustituidas
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201390993A1 (ru) Антитела к cd38
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112012019098B8 (pt) anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica
EA201290727A1 (ru) Пирролбензодиазепины и их конъюгаты
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.